Piper Sandler Raises Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target to $18.00

Catalyst Pharmaceuticals (NASDAQ:CPRXGet Rating) had its target price upped by Piper Sandler to $18.00 in a research report report published on Wednesday morning, Stock Target Advisor reports.

A number of other equities research analysts have also recently issued reports on the company. Truist Financial upped their price objective on Catalyst Pharmaceuticals from $12.00 to $17.00 and gave the stock a buy rating in a research note on Thursday, August 11th. Roth Capital cut Catalyst Pharmaceuticals from a buy rating to a neutral rating and upped their price objective for the stock from $10.00 to $15.50 in a research note on Wednesday, August 24th. HC Wainwright upped their price objective on Catalyst Pharmaceuticals from $12.00 to $18.00 and gave the stock a buy rating in a research note on Thursday, August 11th. Finally, StockNews.com cut Catalyst Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Wednesday, November 9th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus target price of $17.13.

Catalyst Pharmaceuticals Stock Performance

NASDAQ CPRX opened at $15.59 on Wednesday. Catalyst Pharmaceuticals has a 52 week low of $5.24 and a 52 week high of $17.22. The stock has a market capitalization of $1.62 billion, a price-to-earnings ratio of 25.56 and a beta of 1.27. The stock’s 50 day moving average price is $13.64 and its two-hundred day moving average price is $10.86.

Insider Buying and Selling

In related news, COO Steve Miller sold 107,933 shares of the business’s stock in a transaction that occurred on Tuesday, September 13th. The stock was sold at an average price of $16.90, for a total transaction of $1,824,067.70. Following the transaction, the chief operating officer now directly owns 653,791 shares of the company’s stock, valued at approximately $11,049,067.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, COO Steve Miller sold 107,933 shares of the business’s stock in a transaction that occurred on Tuesday, September 13th. The stock was sold at an average price of $16.90, for a total transaction of $1,824,067.70. Following the transaction, the chief operating officer now directly owns 653,791 shares of the company’s stock, valued at approximately $11,049,067.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Alicia Grande sold 90,000 shares of the company’s stock in a transaction on Friday, September 16th. The shares were sold at an average price of $13.50, for a total value of $1,215,000.00. Following the completion of the transaction, the chief financial officer now directly owns 267,442 shares in the company, valued at $3,610,467. The disclosure for this sale can be found here. In the last three months, insiders have sold 651,793 shares of company stock valued at $9,800,939. 14.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CPRX. FMR LLC grew its holdings in Catalyst Pharmaceuticals by 24.2% in the 2nd quarter. FMR LLC now owns 4,218 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 822 shares in the last quarter. Covestor Ltd lifted its position in shares of Catalyst Pharmaceuticals by 768.0% during the 1st quarter. Covestor Ltd now owns 4,878 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 4,316 shares during the period. Quantbot Technologies LP bought a new stake in shares of Catalyst Pharmaceuticals during the 1st quarter valued at $62,000. Quantamental Technologies LLC bought a new stake in shares of Catalyst Pharmaceuticals during the 2nd quarter valued at $72,000. Finally, Point72 Hong Kong Ltd lifted its position in shares of Catalyst Pharmaceuticals by 63.0% during the 1st quarter. Point72 Hong Kong Ltd now owns 9,670 shares of the biopharmaceutical company’s stock valued at $80,000 after acquiring an additional 3,738 shares during the period. 74.16% of the stock is owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Company Profile

(Get Rating)

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

Further Reading

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.